Clarithromycin/Clofazimine/Rifabutin

克拉霉素/氯法齐明/利福布汀

Report date: 2026/03/04 20:01:44
QIDP

Base Information

Drug NameClarithromycin/Clofazimine/Rifabutin
Drug Alias NameClarithromycin/rifabutin/clofazimine氯法齐明/利福布汀/克拉霉素Clofazimine/clarithromycin/rifabutin利福布汀/克拉霉素/氯法齐明Clofazimine/rifabutin/clarithromycin +[15] 
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of ActionDNA inhibitorsBacterial DNA-directed RNA polymerase inhibitors50S ribosomal subunit inhibitors
Targets50S ribosomal subunitBacterial DNA-directed RNA polymeraseDNA
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingLung DiseasesBronchiectasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[10] 
CombinationsYes ClarithromycinClofazimineRifabutin
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentre For Digestive Diseases
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRedhill Biopharma Ltd
Active IndicationsLung DiseasesBronchiectasisMycobacterium Infections
Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingCrohn Disease

Other Information

ATC CodeN/A
Related LinksN/A